CytoDyn Names Robert E. Hoffman CEO, Succeeding Jacob Lalezari

Bitget2026/10/19 20:50

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

CytoDyn appointed principal accounting officer Robert E. Hoffman CEO, effective Oct. 20, 2026, replacing Jacob Lalezari.
Lalezari, CEO since November 2023, will become head of research and translational sciences, focusing on new solid-tumor oncology opportunities for leronlimab.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610191650PRIMZONEFULLFEED9848643) on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

CytoDyn Names Robert E. Hoffman CEO, Succeeding Jacob Lalezari

You may also like

Crypto prices